Deutsche Private Equity

We focus equally on scope for development, time and genuine partnerships with management.

Our News

CENTOGENE raises a EUR 25 million Series A financing to fuel innovation and to accelerate growth into personalized medicine

  • International consortium of investors is led by TVM Capital Life Science together with DPE Deutsche Private Equity, Careventures and CIC Capital
  • CENTOGENE will continuously expand its R&D activities, including biomarkers and companion diagnostic solutions, as well as broadening its global genetic diagnostics activities for early and precise diagnosis and treatment of rare diseases

Rostock/Berlin, 13. June 2017 – CENTOGENE AG, a worldwide leader in the field of genetic diagnostics for rare diseases, announced today its 25 million EUR Series A financing round led by TVM Capital Life Science in collaboration with DPE Deutsche Private Equity, Careventures and CIC Capital. The proceeds of the financing will be used to accelerate the company’s further growth and expansion plans in the business segments of worldwide Genetic Testing, Pharmaceutical Collaborations and Big Data-Solutions. CENTOGENE AG already commands the largest test portfolio for rare genetic diagnostics in the world having analyzed patients from over 110 countries, allowing CENTOGENE to generate unique and global insights into the epidemiological basis of hereditary disorders and the link between genotypic and phenotypic data. “There is a large unmet need for early and easy diagnosis and treatment of rare hereditary diseases. This creates a tremendous market opportunity for us”, comments Prof. Arndt Rolfs, MD, CEO and Founder of CENTOGENE AG. “We are very pleased to have this international investor consortium on board who not only shares our vision for future growth to put innovation into precision medicine, but also provides the necessary access to an international network to realize our vision on a real global basis.”

CENTOGENE aims to increase its presence in the U.S. and China and intends to expand its current presence in other regions, mainly in the MENA region and Latin America. Additionally, the funding will enable the company to broaden its portfolio of biomarkers, companion diagnostics and tools for oncogenetics.

“We are very glad to support a highly innovative company, already a world leader in its field, on its journey towards innovating modern medicine, genetic diagnostics and the treatment of genetic diseases”, adds Dr. Hubert Birner, Managing Partner, TVM Capital Life Science. “CENTOGENE, headquartered in Rostock, is the second investment in the history of TVM Capital Life Science residing in the federal state of Mecklenburg-Western Pomerania. That proves that Germany’s vibrant life sciences and biotech industry is widespread across the country.”

“CENTOGENE’s genetics database coupled with its in-depth clinical knowledge ideally positions the company to continue on its growth trajectory. It uniquely addresses the challenges of the pharmaceutical industry in a market that develops towards evidence-based and personalized medicine”, notes Guido Prehn, Partner at DPE Deutsche Private Equity.

“We are proud to support one of the world leaders in genetic testing and biomarkers discovery. With an exceptional scientific and development team, we are confident that CENTOGENE will strengthen its presence over the five continents”, says Eric Souetre, Managing Partner of Careventures.

“We are very happy that the investment in CENTOGENE, a company with strong fundamentals, is the first implementation of our new international strategy in Germany aiming at investing in growing midsize companies alongside renowned investors”, comments Sébastien Neiss, Director in charge of Germany for CIC Capital.

Dr. Hubert Birner, TVM Capital Life Science, Eric Souetre, Careventures and Guido Prehn, DPE Deutsche Private Equity, will join the Supervisory Board of the company.

Back to News